Selecting biologics for Medicare price negotiations may deliver early savings but could limit long-term reductions through biosimilar competition. The first negotiated prices, effective January 2026, ...
Third-party purchasers of the Stelara drug won partial class action certification in a case accusing Johnson & Johnson of delaying less expensive versions of the medication that treats Crohn’s disease ...
Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader macroeconomic uncertainties. Here, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback